Placebo News and Research

RSS

Promising clinical trial for patients with obsessive-compulsive disorder

Obsessive-compulsive disorder (OCD) affects 2% of the population and is considered a psychiatric disorder. It is the number four psychiatric pathology in terms of frequency following phobias, disorders relating to alcohol and drugs, and depression.

12 Nov 2008

Taking calcium and vitamin D supplements does not reduce breast cancer risk

Taking calcium and vitamin D supplements does not reduce breast cancer incidence in postmenopausal women, according to data from a randomized, doubled-blind, placebo-controlled trial published online November 11 in the Journal of the National Cancer Institute.

11 Nov 2008

Large trial on low-dose aspirin in diabetics

Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association's Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events in those over 65 years of age, and a reduction in cerebrocardiovascular deaths.

11 Nov 2008

Folic acid does not offer any cardiovascular benefits

Folic acid is safe - but it lacks any cardiovascular benefits - according to researchers presenting at the American Heart Association's Scientific Sessions 2008. The results from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), a 12,064-person, randomized study, were presented as a late-breaking clinical trial.

11 Nov 2008

Rivaroxaban shows promise in patients with acute coronary syndrome

Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Interferon eliminates specific causes of some viruses in heart failure patients, improving clinical outcomes

Giving interferon to heart failure patients with evidence of a chronic viral infection safely eliminated two viruses from their systems and reduced levels of a third virus.

11 Nov 2008

New advances in diagnosis and treatment of allergic diseases

Researchers are presenting more than 450 abstracts on investigational findings in the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Seattle, Nov. 6-11. Following are highlights of some key studies in allergy-immunology.

11 Nov 2008

Trial of investigational drug for treatment of advanced heart failure

UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure.

10 Nov 2008

Gene therapy for advanced heart failure shows promising results

Phase I results of the first clinical trial of gene therapy for patients with advanced heart failure show the approach to be promising, with improvements in several measures of the condition's severity.

10 Nov 2008

Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles

Resverlogix Corp. has announced key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

10 Nov 2008

Testosterone patches charge up older women's sex

According to research by an international team of scientists testosterone could recharge the sex lives of older women.

10 Nov 2008

Vitamins C and E do not prevent cardiovascular disease in men

Neither vitamin E nor vitamin C supplements reduced the risk of major cardiovascular events in a large, long-term study of male physicians, according to a study in the November 12 issue of JAMA.

10 Nov 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

Beta-alanine supplement shows strong effects in the elderly

Beta-alanine (BA), a dietary supplement widely used by athletes and body builders, has been proven to increase the fitness levels of a group of elderly men and women.

7 Nov 2008

Coping and copulation behavior may help calculate diabetes risk

Discussion of a man's background, attitude, and sexual history isn't just the fodder of Sex and The City episodes - in the future, it could also be a way of evaluating his risk of diabetes.

7 Nov 2008

Saw Palmetto for enlarged prostate

Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.

6 Nov 2008

Investigational drug, MK-677 shows promise for reducing age-related frailty

Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty.

5 Nov 2008